Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor with high lethality. Even with surgery, radiotherapy, chemotherapy, and other locoregional or systemic therapies, the survival rates for PDAC are low and have not significantly changed in the past decades. The special characteristics of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostios-Garcia, Lorena, Villamayor, Julia, Garcia-Lorenzo, Esther, Vinal, David, Feliu, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567475/
https://www.ncbi.nlm.nih.gov/pubmed/34790007
http://dx.doi.org/10.3748/wjg.v27.i40.6775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567475/
https://www.ncbi.nlm.nih.gov/pubmed/34790007
http://dx.doi.org/10.3748/wjg.v27.i40.6775

Ejemplares similares